News
Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback